154 related articles for article (PubMed ID: 37796807)
21. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
[TBL] [Abstract][Full Text] [Related]
23. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
[TBL] [Abstract][Full Text] [Related]
24. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
[TBL] [Abstract][Full Text] [Related]
25. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
[TBL] [Abstract][Full Text] [Related]
26. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
27. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
[TBL] [Abstract][Full Text] [Related]
28. Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
Trapani D; Crimini E; Sandoval J; Curigliano G
Cancer Treat Res; 2023; 188():343-351. PubMed ID: 38175352
[TBL] [Abstract][Full Text] [Related]
29. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
Li W; Qiu T; Guo L; Ying J; Zhou A
Pathol Res Pract; 2019 Mar; 215(3):483-489. PubMed ID: 30611619
[TBL] [Abstract][Full Text] [Related]
30. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
31. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
32. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
33. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
[TBL] [Abstract][Full Text] [Related]
34. Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay.
Selvam P; Hsiao MC; Omerza G; Bergeron D; Rowe S; Uvalic J; Soucy M; Peracchio M; Burns S; Meyers B; Prego M; Nie Q; Ananda G; Chandok H; Kelly K; Hesse A; Reddi HV
Mol Diagn Ther; 2020 Feb; 24(1):103-111. PubMed ID: 31754995
[TBL] [Abstract][Full Text] [Related]
35. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
37. Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.
Mauri D; Kamposioras K; Matthaios D; Tolia M; Nixon I; Dambrosio M; Zarkavelis G; Papadimitriou K; Petricevic B; Kountourakis P; Kopecky J; Grašič Kuhar C; Popovic L; Chilingirova NP; De Mello RA; Dedić Plavetić N; Katsanos K; Mostert B; Alongi F; de Bari B; Corradini S; Kampletsas E; Gazouli I; Gkoura S; Amylidi AL; Valachis A
Oncol Res Treat; 2022; 45(4):216-221. PubMed ID: 34999585
[TBL] [Abstract][Full Text] [Related]
38. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study.
Kang S; Yu YL; Cho SY; Park SY
Eur J Cancer; 2020 Dec; 141():185-192. PubMed ID: 33166861
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
